- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04601116
The MASTER Study (MAmmary Cancer STatin ER Positive Study)
A Randomized, Multicenter, Double-blind, Placebo-controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Placebo Versus Standard (Neo)Adjuvant Therapy Plus Atorvastatin in Patients With Early Breast Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Cholesterol-lowering drugs such as statins are currently used to lower cholesterol levels and prevent cardiovascular events. Statins have, however, received substantial scientific attention as cancer-inhibiting drugs. Previous findings were recently supported in a large-scaled study again demonstrating the beneficial effects of statins on breast cancer outcome this time nested within a large, international, randomized clinical trial of modern adjuvant cancer therapy. Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. Thus, the primary objective of the MASTER trial is to determine the clinical efficacy of the statin - atorvastatin - as measured by invasive disease-free survival among patients with primary breast cancer.
The trial is nationwide throughout Denmark and a total of 3,360 women are to be included in the trial. Women eligible for the trial have been diagnosed with an estrogen receptor positive breast cancer and are candidates for systemic cancer therapy, either prior to or following breast surgery. Upon eligibility and signed informed consent, trial participants will be randomized in a 1:1 manner to either standard treatment and atorvastatin 80 mg/day or standard treatment and placebo. The randomization is blinded. The treatment with atorvastatin or placebo will continue for two years unless side effects are experienced and further treatment with atorvastatin or the placebo is deemed inadequate. The standard treatment will of course continue as planned. The trial participants will follow the standard clinical routines in terms of follow-up and in addition they are asked to fill in questionnaires, i.e. regarding potential side effects or new events or diagnoses, up to ten years following inclusion. Potential breast cancer recurrences are hereby identified and a follow-up of at least 61/2 years will be required for the trial the demonstrate the estimated clinical difference between the randomized groups of patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Signe SB Borgquist, MD, PhD
- Phone Number: 004522624525
- Email: signe.borgquist@auh.rm.dk
Study Locations
-
-
-
Aarhus, Denmark
- Recruiting
- Aarhus University Hospitak
-
Contact:
- Signe SB Borgquist, MD, PhD
- Phone Number: 004522624525
- Email: signe.borgquist@auh.rm.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients must meet ALL of the following criteria to be eligible for randomization:
Inclusion Criteria:
- Women with estrogen receptor positive breast cancer who are candidates for (neo)adjuvant systemic therapy OR have received ≤3 years of adjuvant endocrine therapy.
- Age > 18 years.
- Performance status of ECOG ≤ 2.
- Prior to patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
Patients meeting ANY one of the following criteria are not eligible:
Exclusion Criteria:
- History of any prior (ipsi- and/or contralateral) invasive breast carcinoma.
- Ongoing (prevalent) cholesterol-lowering therapy (statins, fibrates, ezetimibe, PCSK9 inhibitors). If so, the patient can be enrolled in the observational arm.
- Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range) or renal dysfunction (creatinine level more than three times the upper limit of the normal range).
- Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle - or liver disease, or excessive alcohol consumption AND creatine kinase (CK) measured to less than five times the upper limit (CK only measured in case of predisposing factors).
- No current medication with potent CYP3A4-inhibitors (e.g. ketokonazole, erythromycin) or gemfibrozile, cyclosporin or danazol.
- Pregnancy or breast-feeding.
- Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial.
- History of allergic reactions attributed to compounds of similar chemical or biological composition to atorvastatin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Atorvastatin 80 Mg Oral Tablet
Atorvastatin 80 mg tablets per day for 2 years
|
Atorvastatin 80 mg per day for 2 years
|
Placebo Comparator: Placebo
Placebo tablets 1 per day for 2 years.
|
Placebo 1 tablet per day for 2 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Invasive disease-free survival
Time Frame: 10 years
|
Invasive disease-free survival (IDFS), defined as the time from randomization until the date of the first occurrence of one of the following events:
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distant-recurrence free interval
Time Frame: 10 years
|
Distant-recurrence free interval defined as time from inclusion to first distant recurrence including associations with first site of recurrence.
|
10 years
|
Recurrence-free interval
Time Frame: 10 years
|
Recurrence-free interval including associations with first site of recurrence
|
10 years
|
Overall survival.
Time Frame: 10 years
|
Overall survival.
|
10 years
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTC-AE, 5.0
Time Frame: 10 years
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTC-AE, 5.0
|
10 years
|
Cardiac death-free interval
Time Frame: 10 years
|
Cardiac death-free interval. Cardiac death is defined as:
|
10 years
|
Co-morbidity
Time Frame: 10 years
|
Co-morbidity incidence beyond cardiovascular events during follow-up including diagnoses such as diabetes mellitus.
|
10 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Signe SB Borgquist, MD, PhD, Aarhus University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBMASTER
- 2019-002508-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
Clinical Trials on Atorvastatin 80 Mg Oral Tablet
-
Montefiore Medical CenterNot yet recruiting
-
Damanhour UniversityTanta UniversityCompletedDyslipidemia Associated With Type II Diabetes MellitusEgypt
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Taipei Medical University Shuang Ho HospitalUniversity of Southern CaliforniaEnrolling by invitationChronic Kidney Diseases | Autosomal Dominant Polycystic Kidney DiseaseTaiwan
-
Enteris BioPharma Inc.Syneos Health; ParexelRecruitingEndometriosisUnited States
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institute on Aging... and other collaboratorsRecruitingCardiovascular Diseases | Dementia | Cognitive Impairment, MildUnited States, Puerto Rico
-
University of CologneGerman Federal Ministry of Education and ResearchCompletedCoronary Artery DiseaseGermany
-
Tanta UniversityRecruitingHyperuricemia | Non Alcoholic SteatohepatitisEgypt
-
Cassava Sciences, Inc.National Institute on Aging (NIA)Completed
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States